Risk factors for infection during treatment with peginterferon alfa and ribavirin for chronic hepatitis C
Robert Roomer, Bettina E. Hansen, Harry L. A. Janssen, Robert J. de Knegt – 29 July 2010 – Neutropenia during treatment with peginterferon alfa and ribavirin for chronic hepatitis C virus (HCV) infection is a common cause of dose reductions of peginterferon alfa. These reductions are performed to prevent bacterial and fungal infections, which are common during HCV treatment and can be attributed to neutropenia. The aims of this study were to investigate the occurrence of infections and their relation to neutropenia and to identify potential risk factors for infections during HCV treatment.